Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Silvia Ling, John Allen, Simon J. Harrison et al.|Haematologica|2011Cited by 129
Pretransplant MRD detection of fusion transcripts is strongly prognostic in <i>KMT2A-</i>rearranged acute myeloid leukemiaSun Loo, Andrew H. Wei, Nicola Potter et al.|Blood|2024Cited by 13
Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in <i>NPM1</i> mutated or <i>KMT2A-</i>rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform TrialSun Loo, Andrew H. Wei, Harry Iland et al.|Blood|2024Cited by 9
Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemiaIbrahim Aldoss, Elias Jabbour, Gail J. Roboz et al.|The Lancet Haematology|2024Cited by 4